The CD83 axis between Tregs and CCR7+ dendritic cells governs anti-tumor immune responses 2309951
Immune checkpoint blockade (ICB) has advanced the treatment of melanoma and other cancer types. Despite its success, only about half of the treated patients respond, with many developing resistances. One contributing factor is the poor infiltration of effector T cells in the solid tumors, along with the immunosup...